Status:
UNKNOWN
To Evaluate Safety and Effectiveness of RovatitanTab.
Lead Sponsor:
LG Chem
Conditions:
Hypertension
Hyperlipidemias
Eligibility:
All Genders
19+ years
Brief Summary
To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia
Detailed Description
* Effectiveness: the ratio of patients who reach target BP or LDL-cholesterol * Safety: we will collect safety data
Eligibility Criteria
Inclusion
- Patients who have hypertension and hyperlipidemia and older than 19 years
- Patients who undertstand purpose and method of study, agree with study
Exclusion
- Patients who have been administered Rosuvastatin/Valsartan as a anti- hyperlipiddemic/anti-hypertensive drugs
- Uncontrolled hypertension (SBP\>=180mmHg or DBP\>=110mmHg)
- Patients who participated another clinical study or observational study 3 months ago.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04398771
Start Date
September 1 2020
End Date
May 31 2022
Last Update
May 21 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.